Q3 EPS Forecast for Oruka Therapeutics Decreased by Analyst

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Research analysts at HC Wainwright cut their Q3 2026 earnings per share (EPS) estimates for shares of Oruka Therapeutics in a report released on Thursday, September 3rd. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($0.66) per share for the quarter, down from their previous estimate of ($0.47). HC Wainwright currently has a “Buy” rating and a $120.00 target price on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Oruka Therapeutics’ Q4 2026 earnings at ($0.65) EPS, FY2026 earnings at ($2.54) EPS, Q1 2027 earnings at ($0.67) EPS, Q2 2027 earnings at ($0.69) EPS, Q3 2027 earnings at ($0.72) EPS and FY2027 earnings at ($2.82) EPS.

Oruka Therapeutics (NASDAQ:ORKA) last issued its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04).

Several other equities analysts have also commented on ORKA. UBS Group increased their target price on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Piper Sandler restated an “overweight” rating and set a $180.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Weiss Ratings upgraded Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. Wedbush reissued an “outperform” rating and issued a $165.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Finally, Mizuho set a $120.00 target price on Oruka Therapeutics in a report on Thursday. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $133.00.

Oruka Therapeutics Stock Performance

Shares of ORKA opened at $92.51 on Monday. The firm has a market cap of $6.13 billion, a price-to-earnings ratio of -45.57 and a beta of -0.34. Oruka Therapeutics has a fifty-two week low of $14.66 and a fifty-two week high of $115.51. The firm has a 50 day moving average price of $95.24 and a 200-day moving average price of $70.27.

Insider Activity

In other Oruka Therapeutics news, CEO Lawrence Klein sold 75,000 shares of the business’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $91.83, for a total value of $6,887,250.00. Following the transaction, the chief executive officer owned 925,580 shares in the company, valued at approximately $84,996,011.40. The trade was a 7.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,000 shares of the company’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $111.84, for a total transaction of $782,880.00. Following the transaction, the insider directly owned 32,718 shares of the company’s stock, valued at approximately $3,659,181.12. This trade represents a 17.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 158,116 shares of company stock worth $13,523,783 in the last quarter. Insiders own 23.49% of the company’s stock.

Institutional Investors Weigh In On Oruka Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ORKA. Goldman Sachs Group Inc. purchased a new position in shares of Oruka Therapeutics during the first quarter valued at approximately $2,505,000. JPMorgan Chase & Co. lifted its stake in Oruka Therapeutics by 567.7% in the second quarter. JPMorgan Chase & Co. now owns 15,425 shares of the company’s stock worth $173,000 after acquiring an additional 13,115 shares during the period. Legal & General Group Plc purchased a new stake in Oruka Therapeutics in the second quarter worth $28,000. Rhumbline Advisers bought a new stake in Oruka Therapeutics in the second quarter valued at $320,000. Finally, New York State Common Retirement Fund purchased a new position in Oruka Therapeutics during the 2nd quarter valued at $96,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.